Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

A faster, cheaper alternative to karyotyping, DNA index testing shows near-perfect accuracy for detecting high hyperdiploidy in pediatric patients with leukemia.

A new review explains how new therapies and technologies are guiding the treatment of acute myeloid leukemia (AML).

A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age populations, explains Tina Bhatnagar, DO.

Posttransplant gilteritinib maintenance therapy may boost survival and reduce relapse in relapsed FLT3-mutated acute myeloid leukemia (AML), but larger trials are still needed.

A new approach to posttransplant prophylaxis for graft vs host disease promises to increase access to the procedure to patients from minority groups with blood cancers. Investigators are now studying a lower dose of the treatment to limit toxicity.

Racial and ethnic disparities in outcomes persist in acute myeloid leukemia, but such disparities may not be tied to the use of tyrosine kinase inhibitors, according to a new report.

Oncology has never had more to offer, and yet it is straining under the weight of its own progress.

Early treatment for acute promyelocytic leukemia likely improves mother-baby outcomes, with treatment timing guiding safer delivery.

Patient-reported data can predict survival in leukemia, and integrating measuring tools improves care by prioritizing the patient's perspective.

Bhavana (Tina) Bhatnagar, DO, advocates for AI and diverse clinical trials to bridge equity gaps in precision oncology and value-based care.

The combination regimen is so effective because DAC has several mechanisms through which it exerts antileukemic effects.

A Quebec cohort study links gas station proximity to higher VOC exposure and elevated childhood cancer risk, especially acute lymphoblastic leukemia.

Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk.

Disparities in access to allo-HCT for AML persist, highlighting the need for targeted interventions to ensure equitable treatment for all patients.

Ongoing phase 3 trials target improved therapies for hematologic malignancies, focusing on CLL, multiple myeloma, and pediatric leukemia outcomes.

Reduced doses and shorter durations of venetoclax can enhance treatment outcomes and reduce adverse events in acute myeloid leukemia (AML).

ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life while reducing burdens.

Top articles in 2025 covered advancements in acute myeloid leukemia treatments, including allogeneic CAR T-cell therapy.

Blinatumomab enhances survival in pediatric B-cell ALL, yet homecare challenges hinder its outpatient delivery.

Financial and social barriers hinder access to specialized care and impact treatment outcomes for adolescents and young adults with leukemia.

Olutasidenib shows promising long-term efficacy and safety in treating relapsed or refractory mutant IDH1 acute myeloid leukemia.

Pretransplant NPM1 MRD testing significantly predicts relapse risk in acute myeloid leukemia.

Patients achieve a high 2-year survival and deep MRD-negative remissions with CAR T-cell therapy followed by stem cell transplant in B-cell ALL.

Clark Alsfeld, MD, discusses how telemedicine, pharmacists, and evolving policies help overcome financial and geographic barriers in oncology care.